TARS News and Press, Tarsus Pharmaceuticals Inc. From 02/02/24

2024-02-02 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chi...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 2.73% on the day to $14.13. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development...

2024-01-22 12:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-11 20:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

2023-12-27 17:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, today announced topline results from the Ersa Phase 2a clinical trial evalua...

2023-12-05 12:00:00 ET Summary In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top in...

2023-12-04 12:09:00 ET Summary TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23....